A) HEY/NIH

Rank	Efficacy (max resp. ATP)		Potency (IC_{50} ATP (µM))		Therapeutic window (3-day)		Therapeutic window (7-day)		Effect on tumor size (tumor growth % of control)	
	Compound name	Value	Compound name	Value	Compound name	Value	Compound name	Value	Compound name	Value
1	Bardoxolone methyl	0,127	Romidepsin	0,005	Romidepsin	*infinite	Salinomycin	*infinite	HLI-373989	1,801
2	Obatoclax	0,312	TAK-733	0,007	G-Strophanthin	*infinite	DA-3003-1	*infinite	Romidepsin	17,44
3	*Sepant. brom.	0,349	Cycloheximide	0,022	Dasatinib	*infinite	TAK-733	161,6	*Topotecan hydr.	21,65
4	Ponatinib	0,353	*Topotecan hydr.	0,025	Digoxin	*infinite	Dasatinib	158,7	*Sepant. brom.	24,39
5	Carfilzomib	0,463	Torin-2	0,027	*Sepant. brom.	*infinite	*Sepant. brom.	55,19	PD-173955	36,35
6	Sunitinib malate	0,469	Ponatinib	0,055	HMSL10084	*infinite	Cycloheximide	51,86	TAK-733	40,463
7	TAE-684	0,481	SR-3306	0,058	PD-173955	*infinite	TAE-684	31,91	Amiodarone	51,87
8	SR-3306	0,574	Carfilzomib	0,067	AV-412	*infinite	Ponatinib	29,71	Benzamil	52,07
9	HLI-373989	0,869	G-Strophanthin	0,070	Bardoxolone methyl	*infinite	PD-173955	20,37	Dasatinib	54,26
10	DA-3003-1	0,872	Dasatinib	0,077	Salinomycin	*infinite	Carfilzomib	12,85	Cycloheximide	57,07

***Sepant. brom.: Sepantronium bromide; *Topotecan hydr.: Topotecan hydrochloride**

***infinite: the therapeutic window of a compound was assumed to be infinite when no significant effect on the fibroblasts has been verified in reference to the vehicle control at highest drug concentration (20µM)**

B) SKOV/NIH

Rank	Efficacy (max resp. ATP)		Potency (IC_{50} ATP (µM))		Therapeutic window (3-day)		Therapeutic window (7-day)		Effect on tumor size (tumor growth % of control)	
	Compound name	Value	Compound name	Value	Compound name	Value	Compound name	Value	Compound name	Value
1	Bardoxolone methyl	0,265	Bardoxolone methyl	0,000	Bardoxolone methyl	*infinite	Dasatinib	*infinite	HMSL10084	7,309
2	AV-412	0,465	Torin-2	0,002	Torin-2	*infinite	VU0483488-1	*infinite	GM-6001	13,91
3	Ponatinib	0,505	Romidepsin	0,003	Dasatinib	*infinite	PNU-74654	*infinite	TAE-684	19,85
4	Romidepsin	0,529	TAK-733	0,013	AV-412	*infinite	WAY-600	*infinite	Salinomycin	28,17
5	Obatoclax	0,637	SR-3306	0,013	Salinomycin	*infinite	GSK-25	*infinite	SR-3306	29,39
6	TAE-684	0,694	Dasatinib	0,019	WAY-600	*infinite	AV-412	28,42	PNU-74654	35,94
7	Carfilzomib	1,082	Carfilzomib	0,035	Obatoclax	*infinite	Carfilzomib	10,14	Carfilzomib	38,88
8	Sunitinib malate	1,084	AV-412	0,080	VU0483488-1	*infinite	Torin-2	6,000	Sunitinib malate	40,85
9	SR-3306	1,230	Ponatinib	0,233	Sunitinib malate	*infinite	Salinomycin	5,274	Ponatinib	43,73
10	HMSL10084	1,759	Salinomycin	0,274	PNU-74654	*infinite	SR-3306	3,692	Obatoclax	50,75

***infinite: the therapeutic window of a compound was assumed to be infinite when no significant effect on the fibroblasts has been verified in reference to the vehicle control at highest drug concentration (20µM)**

Supplementary Table 5

C) PANC-1/NIH

Rank	Efficacy (max resp. ATP)		Potency (IC_{50} ATP (µM))		Therapeutic window (3-day)		Therapeutic window (7-day)		Effect on tumor size (tumor growth % of control)	
	Compound name	Value	Compound name	Value	Compound name	Value	Compound name	Value	Compound name	Value
1	Ponatinib	0,567	Torin-2	0,001	Romidepsin	*infinite	Bardoxolone methyl	*infinite	HMSL10084	9,832
2	TAE-684	0,682	Romidepsin	0,003	SR-3306	*infinite	Torin-2	540	WAY-600	22,06
3	Carfilzomib	0,984	SR-3306	0,022	TAK-733	*infinite	Carfilzomib	15,47	TAK-733	22,79
4	Salinomycin	1,159	TAK-733	0,025	Ponatinib	*infinite	SR-3306	5,636	Torin-2	29,80
5	SR-3306	1,161	Ponatinib	0,035	Carfilzomib	*infinite	Salinomycin	4,400	Dasatinib	29,97
6	Obatoclax	1,219	Carfilzomib	0,047	Dasatinib	*infinite	Obatoclax	3,878	AV-412	44,35
7	AV-412	1,368	Dasatinib	0,064	Salinomycin	*infinite	Dasatinib	3,578	Salinomycin	48,91
8	Bardoxolone methyl	2,407	Salinomycin	0,377	TAE-684	*infinite	Ponatinib	2,971	GSK-25	49,19
9	Romidepsin	2,764	TAE-684	0,548	HMSL10084	*infinite	TAE-684	2,473	GM-6001	53,83
10	Torin-2	3,342	HMSL10084	0,767	Obatoclax	*infinite	GSK-25	2,466	Bardoxolone methyl	54,27

***infinite: the therapeutic window of a compound was assumed to be infinite when no significant effect on the fibroblasts has been verified in reference to the vehicle control at highest drug concentration (20µM)**

Supplementary Table 4